CD274 and neoplasm: Analysis of tumor immune cell infiltrate demonstrated a significant 30% reduction of MDSCs within the EMT6 tumors treated with the combination of PLX51107 and anti–PD-L1 compared with anti–PD-L1 alone (Figure 6H and Supplemental Figure 14A; P < 0.05 or P < 0.01).